Kevin is a Principal at Polaris Partners.  He joined Polaris in 2004 and focuses on investments in healthcare. Prior to joining Polaris, Kevin completed his PhD in genetics at Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.

Kevin is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics).

Kevin currently represents Polaris as a Director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical, and Vets First Choice. Additionally, Kevin is a Board Observer to Arsenal Medical and 480 Biomedical.